FibroGen, Inc.
FibroGen, Inc. company is focused on developing and commercializing treatments for fibrosis, anemia, diabetes, and cancer, as well as producing recombinant human collagens and synthetic gelatins. FibroGen has several products in clinical development, including: FG-3019, a monoclonal antibody that may treat a variety of conditions including diabetic nephropathy; FG-2216, an orally administered small molecule drug in development for the treatment of anemia; FG-5017, a recombinant version of human collagen; and FG-5009, a synthetic gelatin molecule designed to stabilize vaccines and biologics. The company commenced lab operations in 1995.
Contact Details
Executives
Chairman and CEO
Thomas B. Neff
VP Finance and CFO
Pat Controneo